Sargramostim
Ovarian Serous Cystadenocarcinoma
Explore 6 assets in Ovarian Serous Cystadenocarcinoma →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
University of Washington
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00466960CT.gov Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Serous Cystadenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sargramostim (this asset) | University of Washington | P2 | B · 57 |
| Carboplatin | National Cancer Institute (NCI) | P2 | BB |
| Metformin | University of Chicago | P2 | BB |
| Nivestim | University of Washington | P2 | B |
| Paclitaxel Lipid Suspension | Jina Pharmaceuticals Inc. | P3 | B |
| Nogitecan | Gynecologic Oncology Group | P2 | B |
| Cyclophosphamide | National Cancer Institute (NCI) | P2 | B |
| Urokinase-Derived Peptide A6 | Gynecologic Oncology Group | P2 | B |
| Everolimus | Mayo Clinic | P2 | B |
+20 more in the Ovarian Serous Cystadenocarcinoma cohort
Other indications for Sargramostim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P3 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
| Chronic Myeloid Leukemia | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sargramostim in Ovarian Serous Cystadenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sargramostim-ovarian-serous-cystadenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →